4th Annual International Keloid Symposium

1. Analyze the pathomechanisms of keloid formation.
2. Measure treatment outcomes using new keloid treatment for further analysis by independent observers.
3. Examine pathogenesis to allow for development of newer and more targeted keloid therapies in the future.
4. Evaluate current treatments for keloid disorder.

ECME Credit Conversion

Activities certified for AMA PRA Category 1 Credit™ that take place within a member country of the UEMS are not eligible for conversion to ECMEC®s under the agreement between the American Medical Association (AMA) and the European Union of Medical Specialists (UEMS), the accreditation body for European countries.

(source: https://www.ama-assn.org/education/ama-pra-credit-system/agreement-european-union-medical-specialties-uems)

To learn more about each speaker, click here.

Mitigation of Relevant Financial Relationships

Thomas Jefferson University adheres to the Standards for Integrity and Independence in Accredited Continuing Education and the policies that supplement the Standards.

All planners, faculty, and others in control of educational content are required to disclose any relevant financial relationships with ACCME defined ineligible companies within the past 24 months. Any conflicts of interests have been mitigated prior to this educational activity. Such disclosures will be available prior to the start of the activity. Jefferson conflict of interest mitigation process may result in changes to the program agenda.

Off-Label/Investigational Use
All faculty/presenters/authors at Thomas Jefferson University sponsored events are required to disclose whether or not their content contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. Product(s) is/are not included in the labeling approved by the U.S. FDA for the treatment of disease(s).

Content Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices or Thomas Jefferson University.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

Any commercial or in-kind support received for this activity will be disclosed prior to the start of the activity.